|
|||||
|
|
Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab |
|
| Authors: | Robert K?nigsberg Julia Maierhofer Tanja Steininger Gabriele Kienzer Christian Dittrich |
| Affiliation: | 1. Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) – LB Cluster Translational Oncology, 3rd Medical Department – Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria;2. Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria;3. Institute for Radiodiagnostics, Kaiser Franz Josef-Spital, Vienna |
| Abstract: | BackgroundThe attempt to act on several signalling pathways involved in tumour development simultaneously appears to be more attractive than attacking a single target structure alone. Vascular endothelial growth factor (VEGF) over-expression is frequently observed in human epidermal growth factor receptor 2 (Her2/neu) positive patients with breast cancer and over-expression of the proto-oncogene Her2/neu is associated with an up-regulation of VEGF.Case reportThe case of a Her2/neu positive patient with breast cancer who refused cytotoxic chemotherapy with its potential side effects as well as mastectomy is presented. Our patient has been receiving the combined double administration of bevacizumab and trastuzumab for more than 4 years.ConclusionsThis case report shows that (a) the combined double administration of bevacizumab and trastuzumab was be clinically effective. (b) The combination of bevacizumab and trastuzumab is safe and non-toxic. (c) Bevacizumab and trastuzumab can be used as a long-term application. |
| Keywords: | breast cancer Her2/neu trastuzumab bevacizumab VEGF |